<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02925676</url>
  </required_header>
  <id_info>
    <org_study_id>Pilot 2 Diabetes</org_study_id>
    <nct_id>NCT02925676</nct_id>
  </id_info>
  <brief_title>Evaluation of the Hypoglycaemia Alarm Device Hyposafe H02</brief_title>
  <official_title>Evaluation of the Hypoglycaemia Alarm Device Hyposafe H02 - the Pilot 2 Study - in Subjects With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNEEG Medical A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNEEG Medical A/S</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the technical performance of the hyposafe H02 during everyday activities and
      during insulin-induced hypoglycaemia, in addition to safety issues associated with the
      implantation and use of the hyposafe H02 in subjects with type 1 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sensitivity</measure>
    <time_frame>3 months</time_frame>
    <description>Proportion of spontaneous hypoglycaemic episodes detected by the hyposafe H02 compared to the total number of validated spontaneous hypoglycaemic episodes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Positive predictive value</measure>
    <time_frame>3 months</time_frame>
    <description>Proportion of validated spontaneous hypoglycaemic episodes detected by the hyposafe H02 compared to the total number of alerts from the hyposafe H02</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall sensitivity</measure>
    <time_frame>3 months</time_frame>
    <description>Overall proportion of hypoglycaemic episodes detected by the hyposafe H02 compared to the total number of validated hypoglycaemic episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall positive predictive value</measure>
    <time_frame>3 months</time_frame>
    <description>Overall proportion of validated hypoglycaemic episodes detected by the hyposafe H02 compared to the total number of alerts from the hyposafe H02</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sensitivity during insulin-induced hypoglycaemia</measure>
    <time_frame>2 days</time_frame>
    <description>Proportion of insulin-induced hypoglycaemic episodes detected by the hyposafe H02 compared to the total number of insulin-induced hypoglycaemic episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>positive predictive value for insulin-induced hypoglycaemia</measure>
    <time_frame>2 days</time_frame>
    <description>Proportion of insulin-induced hypoglycaemic episodes detected by the hyposafe H02 compared to the total number of alerts from the hyposafe H02</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EEG quality (power in alpha frequency band) over time</measure>
    <time_frame>start up and after 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in impedance (kOhm) over time</measure>
    <time_frame>start up and after 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device complaints</measure>
    <time_frame>4 months</time_frame>
    <description>Number of device complaints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean glucose level at the time of a hypoglycaemia alarm</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse device effects</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility of using hyposafe H02 on a daily basis based on diary</measure>
    <time_frame>3.5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development in discomfort over time based on questionnaires</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Link strength between the implant and the external device (Volt)</measure>
    <time_frame>3.5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>User satisfaction based on questionnaire</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean number of hours of use per hyposafe H02 device</measure>
    <time_frame>3.5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of correct key press in response to hypoglycaemia alarm</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alarm fatigue based on interview</measure>
    <time_frame>3.5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>User experience in an everyday context based on interview</measure>
    <time_frame>3.5 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>hyposafe H02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects included are assigned to hyposafe H02-testing</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>hyposafe H02</intervention_name>
    <description>hypoglycaemia alarm device</description>
    <arm_group_label>hyposafe H02</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent obtained before any study related activities

          -  Type 1 diabetes diagnosed at least five years prior to inclusion in the study

          -  Impaired awareness and/or history of at least one severe hypoglycaemia within the
             preceding year

        Exclusion Criteria:

          -  Severe cardiac disease

          -  History of stroke or cerebral haemorrhage and any other structural cerebral disease

          -  Active cancer or cancer diagnosis within the past 5 years

          -  Uraemia defined as s-creatinine ≥ 3 times upper reference value

          -  Liver disease defined as s-ALAT ≥ 3 times upper reference interval

          -  Epilepsy

          -  Use of antiepileptic drugs for any indication

          -  Clinically important hearing impairment

          -  Use of active implantable medical device including pacemaker and ICD-unit and cochlear
             implant

          -  Use of following drugs: Chemotherapeutic drugs of any kind, Methotrexate, Third
             generation antipsychotic drugs (aripiprazole, quetiapine, clozapine, ziprasidone,
             paliperidone, risperidone, sertindole, amisulpride, olanzapine)

          -  Contraindications to the local anaesthetic used during implantation

          -  Known or suspected abuse of alcohol or any other neuro-active substances

          -  Infection at the site of device implantation

          -  Any haemorrhagic disease

          -  Females of childbearing potential who are pregnant or intend to become pregnant or are
             not using adequate contraceptive methods throughout the study

          -  Performing extreme sport, including scuba diving (snorkel diving is allowed) or
             parachute jumping

          -  Incapable of understanding the subject information or unlikely to complete the study
             for any reason

          -  Operating MRI scanners

          -  Operating handheld transceivers for communication (e.g. within the police, medical,
             fire, air traffic control, marine or military)

          -  Working at broadcast stations for television or FM/DAB radio
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Birger Thorsteinsson, MD, Dr. Sci</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nordsjællands Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lykke Blaabjerg, MSc, PhD</last_name>
    <phone>+4541414244</phone>
    <email>LB@hyposafe.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kurt Højlund, MD, DMSci</last_name>
    </contact>
    <investigator>
      <last_name>Kurt Højlund, MD, DMSci</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2016</study_first_submitted>
  <study_first_submitted_qc>October 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2016</study_first_posted>
  <last_update_submitted>October 17, 2017</last_update_submitted>
  <last_update_submitted_qc>October 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The main findings of study will be submitted for publication in a peer reviewed journal or made publically available at www.clinicaltrials.gov</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

